Soligenix Inc. Achieves Significant Milestone in Phase 2a Study for Behçet’s Disease Treatment

Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has announced successful outcomes from its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease. The study met its primary objective by demonstrating significant biological efficacy, with a 40% improvement in the primary ulcer endpoint compared to a historical placebo group from the apremilast (Otezla(R)) Phase 3 study. Notably, these results were achieved despite the treatment duration being limited to four weeks, with benefits persisting throughout the follow-up period.

The open-label trial involved eight patients, seven of whom reported reductions in ulcer duration, number, and pain, without any treatment-related adverse events. Christopher J. Schaber, CEO of Soligenix, highlighted the potential of SGX945, including plans for its reformulation for home-based subcutaneous administration, as part of a broader strategy to tackle unmet needs in Behçet’s Disease and other innate immune-related inflammatory conditions. For more details on the study, visit https://ibn.fm/FqcXf.

This advancement underscores Soligenix’s commitment to developing innovative treatments for rare diseases, with SGX945 representing a significant step forward in the management of Behçet’s Disease. The company’s focus on addressing areas of high unmet medical need is further evidenced by its pipeline, which includes potential therapies for cutaneous T-cell lymphoma, psoriasis, and vaccines for public health threats like ricin toxin and COVID-19. For further information on Soligenix and its research initiatives, visit http://www.Soligenix.com.